New lupus drug shows promise in reducing kidney damage

NCT ID NCT03393013

Completed Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tested an experimental drug called KZR-616 in 69 people with lupus, some of whom also had lupus-related kidney disease (lupus nephritis). The goal was to see if the drug is safe and can help control the disease by reducing protein in the urine, a sign of kidney damage. Participants received weekly injections for 13 to 24 weeks. The drug aims to manage the condition, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Academic Medical Research Institute

Los Angeles, California, 990022, United States
Accurate Clinical Management, LLC

Houston, Texas, 77084, United States
Accurate Clinical Research, Inc.

Houston, Texas, 77034, United States
Advent Health Medical Group

Tampa, Florida, 33614, United States
Arthritis Center, Inc

Palm Harbor, Florida, 34684, United States
Bioclinica

Lodz, 90-368, Poland
Centro Integral de Reumatologia SA de CV

Guadalajara, Jalisco, 44160, Mexico
Centro Integral de Reumatologia de Caribe CIRCARIBE S.A.S

Barranquilla, Atlántico, 080020, Colombia
Centro de Investigación Clínica Trujillo E.I.R.L/ Clínica Peruano Americana S.A.

Trujillo, La Libertad, 13011, Peru
Clinica de Artritis Temprana

Cali, Valle del Cauca Department, 076001, Colombia
Clinica de la Costa

Barranquilla, Atlántico, 080020, Colombia
Harmoniya Krasy

Kyiv, Kyiv Governorate, 01135, Ukraine
Hope Clinical Trials, Inc.

Miami, Florida, 33165, United States
Hospital Universitario Dr José Eleuterio Gonzalez

Monterrey, Nuevo León, 64020, Mexico
Inland Rheumatology Clinical Trials, Inc.

Upland, California, 91786, United States
Instituto Nacional de Cardiología Ignacio Chavez

Mexico City, 14080, Mexico
Instituto Nacional de Ciencias Médicas y Nutricion "Salvador Zubiran"

Mexico City, 14080, Mexico
Investigaciones Clinicas SAC

Lima, 15023, Peru
Kuzbass Clinical Hospital

Kemerovo, 650066, Russia
MedResearch, Inc.

El Paso, Texas, 79902, United States
Medical Center Revma-Med

Kemerovo, 650070, Russia
Medicity SAS

Santander, Bucaramanga, 680003, Colombia
Monash Health

Clayton, Victoria, 3168, Australia
NYU Langone Orthopedic Center - Seligman Center for Advanced Therapeutics

New York, New York, 10016, United States
Northwell Health

Great Neck, New York, 11021, United States
Omega Research Maitland

Orlando, Florida, 32808, United States
Ramesh C. Gupta, MD

Memphis, Tennessee, 38119, United States
SC Nephrology & Hypertension Center, Inc.

Orangeburg, South Carolina, 29118, United States
Servimed S.A.S.

Bucaramanga, Santander Department, 680003, Colombia
SouthCoast Research Center, Inc.

Miami, Florida, 33136, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
The Royal Melbourne Hospital

Parkville, Victoria, 3050, Australia
Tolyatti City Clinical Hospital #1

Tolyatti, 445009, Russia
Unidad de Investigacion en Reumatologia e Inmunologia Clinica San Juan Bautista

Lima, 15431, Peru
University of Iowa

Iowa City, Iowa, 52242, United States
University of Rochester Medical Center

Rochester, New York, 14620, United States

Conditions

Explore the condition pages connected to this study.

LUPUS NEPHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC LUPUS ERYTHEMATOSUS